Treatment with an anti-CCL24 monoclonal antibody (CM-101) attenuated immune cell infiltration and reduced collagen deposition in mice with BLM-induced PF, and deletion of CCL2, CCR2, CCL3 or CCR4 induced therapeutic effects in BLM-induced PF mice. Here, CCR2 is linked to Bloom syndrome.